C-Jun N-terminal kinases
Overview[edit]
C-Jun N-terminal kinases (JNKs) are a group of mitogen-activated protein kinases (MAPKs) that are involved in regulating various cellular processes, including cell proliferation, apoptosis, and inflammation. JNKs are activated in response to stress stimuli, such as cytokines, ultraviolet radiation, and heat shock.
Structure and Isoforms[edit]
JNKs are encoded by three genes: MAPK8, MAPK9, and MAPK10, which produce ten different isoforms through alternative splicing. These isoforms are categorized into two main groups: JNK1, JNK2, and JNK3. JNK1 and JNK2 are ubiquitously expressed, while JNK3 is primarily found in the brain, heart, and testis.
Activation and Function[edit]
JNKs are activated by phosphorylation through the MAPK kinase (MKK) pathway. The upstream kinases, MKK4 and MKK7, phosphorylate JNKs on threonine and tyrosine residues, leading to their activation. Once activated, JNKs translocate to the nucleus where they phosphorylate transcription factors such as c-Jun, ATF2, and Elk-1.
JNKs play a critical role in the regulation of gene expression in response to stress. They are involved in the apoptotic response to DNA damage, and their activity is crucial for the immune response and inflammatory processes.
Clinical Significance[edit]
Dysregulation of JNK signaling has been implicated in various diseases, including cancer, neurodegenerative disorders, and diabetes. In cancer, JNKs can have both tumor-promoting and tumor-suppressing roles, depending on the context. In neurodegenerative diseases, such as Alzheimer's disease, JNKs contribute to neuronal death and neuroinflammation.
Research and Therapeutic Potential[edit]
Due to their involvement in numerous pathological conditions, JNKs are considered potential targets for therapeutic intervention. Inhibitors of JNKs are being investigated for their potential to treat inflammatory diseases, cancer, and neurodegenerative disorders.
